

Why ICER Matters to Clinicians & Patients with Severe Asthma

THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW

- Employs health economists to decide if new drugs are "worth it"
- Influences health coverage and patient access, often negatively




ICER'S APPROACH

- Depends largely on **unrepresentative clinical trials** data
- Relies on metrics that **devalue people** living with chronic conditions and disabilities
- **Fails to capture** quality-of-life factors that matter to patients



CLINICIANS AND PATIENTS WITH SEVERE ASTHMA

- Want access to **new and targeted treatments** that could provide unprecedented relief
- Deserve a **better chance of managing severe asthma** and lowering health disparities
- Shouldn't have to fight for **coverage of life-changing drugs**



CLINICIANS AND PATIENTS SHOULD TELL ICER WHAT MATTERS TO THEM



TAKE ACTION >